| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1047655581 |
| P356 | DOI | 10.1186/1479-5876-12-128 |
| P932 | PMC publication ID | 4030016 |
| P698 | PubMed publication ID | 24884660 |
| P5875 | ResearchGate publication ID | 262781189 |
| P2093 | author name string | Ila Sri Bharati | |
| Milan Makale | |||
| Natsuko Nomura | |||
| Pengfei Jiang | |||
| Rajesh Mukthavaram | |||
| Sandeep C Pingle | |||
| Sandra Pastorino | |||
| Santosh Kesari | |||
| Shireen Vali | |||
| Taher Abbasi | |||
| Ying Chao | |||
| Ashish Agrawal | |||
| Ansu Kumar | |||
| Shweta Kapoor | |||
| Shahabuddin Usmani | |||
| Zeba Sultana | |||
| P2860 | cites work | Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy | Q39447688 |
| Development of human tumor cell line panels for use in disease-oriented drug screening | Q39529613 | ||
| Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment | Q39530855 | ||
| Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. | Q39718152 | ||
| Multiscale agent-based cancer modeling | Q40048012 | ||
| Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. | Q40067799 | ||
| Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells | Q40321992 | ||
| An information-intensive approach to the molecular pharmacology of cancer. | Q41134023 | ||
| Virtual prototyping study shows increased ATPase activity of Hsp90 to be the key determinant of cancer phenotype. | Q41901782 | ||
| Personalizing medicine: a systems biology perspective | Q43142778 | ||
| Identification of molecular subtypes of glioblastoma by gene expression profiling | Q48332534 | ||
| Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers | Q50539670 | ||
| Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis. | Q51930607 | ||
| A mathematical model of glioma growth: the effect of extent of surgical resection. | Q52304032 | ||
| A mathematical model of glioma growth: the effect of chemotherapy on spatio-temporal growth. | Q52358855 | ||
| Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo | Q82738017 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma | Q28286168 | ||
| High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models | Q28486219 | ||
| Systematic identification of genomic markers of drug sensitivity in cancer cells | Q29547695 | ||
| Distinct sets of genetic alterations in melanoma | Q29614965 | ||
| Malignant gliomas in adults | Q29615708 | ||
| Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines | Q29615823 | ||
| A computer simulation of progesterone and Cox2 inhibitor treatment for preterm labor | Q30977313 | ||
| In silico cancer modeling: is it ready for prime time? | Q35540740 | ||
| Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells. | Q35564293 | ||
| Defensin DEFB103 bidirectionally regulates chemokine and cytokine responses to a pro-inflammatory stimulus | Q36589595 | ||
| Elastin sequences trigger transient proinflammatory responses by human dermal fibroblasts | Q37118751 | ||
| A colorectal cancer classification system that associates cellular phenotype and responses to therapy | Q37175913 | ||
| Multiscale cancer modeling | Q37443767 | ||
| A kinetic platform for in silico modeling of the metabolic dynamics in Escherichia coli | Q38364440 | ||
| P921 | main subject | in silico | Q192572 |
| P304 | page(s) | 128 | |
| P577 | publication date | 2014-05-21 | |
| P1433 | published in | Journal of Translational Medicine | Q15716664 |
| P1476 | title | In silico modeling predicts drug sensitivity of patient-derived cancer cells | |
| P478 | volume | 12 |
| Q46093038 | A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. |
| Q96303348 | A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities |
| Q92823232 | A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients |
| Q92215204 | Computational Models Accurately Predict Multi-Cell Biomarker Profiles in Inflammation and Cancer |
| Q47319211 | Computational modeling in glioblastoma: from the prediction of blood-brain barrier permeability to the simulation of tumor behavior. |
| Q38719813 | Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells |
| Q95319800 | IRE1α and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cells |
| Q37392623 | Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines |
| Q38968601 | In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells |
| Q38914605 | Personalization of cancer treatment using predictive simulation |
| Q62516274 | Predicting response to BET inhibitors using computational modeling: A BEAT AML project study |
| Q30977149 | S100A4 and its role in metastasis – computational integration of data on biological networks |
| Q57899349 | Working towards personalization in medicine: main obstacles to reaching this vision from today's perspective |
Search more.